• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/25 4:10:02 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNTH alert in real time by email
    8-K
    false000169058500016905852025-05-122025-05-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 12, 2025

     

     

    DIANTHUS THERAPEUTICS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38541

    81-0724163

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    7 Times Square

    43rd Floor

     

    New York, New York

     

    10036

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 929 999-4055

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 Par Value

     

    DNTH

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 12, 2025, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

     

    The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    99.1

    Press release dated May 12, 2025

    104

    Cover Page Interactive Data File (embedded within the inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    DIANTHUS THERAPEUTICS, INC.

     

     

     

     

    Date:

    May 12, 2025

    By:

    /s/ Adam M. Veness, Esq.

     

     

     

    Adam M. Veness, Esq.
    SVP, General Counsel and Secretary

     


    Get the next $DNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNTH

    DatePrice TargetRatingAnalyst
    12/20/2024Buy
    TD Cowen
    10/3/2024$48.00Outperform
    Oppenheimer
    7/26/2024$58.00Outperform
    Robert W. Baird
    6/27/2024Overweight
    Cantor Fitzgerald
    5/16/2024$40.00Buy
    H.C. Wainwright
    2/15/2024$44.00Buy
    Stifel
    12/26/2023$22.00Buy
    Jefferies
    11/22/2023$23.00Outperform
    Wedbush
    More analyst ratings

    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Dianthus Therapeutics

      TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

      12/20/24 7:31:45 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Dianthus Therapeutics with a new price target

      Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00

      10/3/24 7:28:24 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Dianthus Therapeutics with a new price target

      Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00

      7/26/24 7:27:12 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

      NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors. A live webcast of the Company's presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Diant

      5/29/25 7:00:00 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

      Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

      5/22/25 4:10:00 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

      Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage

      5/12/25 4:01:46 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Violin Jonathan

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      5/22/25 4:44:50 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Soteropoulos Paula

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      5/22/25 4:43:34 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Romano Steven J.

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      5/22/25 4:42:58 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

      Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

      5/22/25 4:10:00 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

      Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

      3/5/25 7:00:00 AM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

      Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

      11/29/23 4:05:00 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    SEC Filings

    See more
    • Dianthus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      5/22/25 4:05:54 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Dianthus Therapeutics Inc.

      SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      5/15/25 4:55:02 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Dianthus Therapeutics Inc.

      10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      5/12/25 4:14:25 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

      SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      12/3/24 9:19:18 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Dianthus Therapeutics Inc.

      SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      11/22/24 4:41:50 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      11/14/24 5:48:32 PM ET
      $DNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care